90 studies found for:    myeloma AND (women OR woman OR female)
Show Display Options
Download search resultsDownload the search results for:
myeloma AND (women OR woman OR female) (90 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Terminated A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: 5.0g SRT501;   Drug: Bortezomib
2 Completed Stem Cell Transplantation in Individuals With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Tandem Autologous Transplant;   Drug: Autologous Transplant Plus Non-Myeloablative Allogeneic Transplant
3 Completed Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: Dendritic Cell Tumor Fusion
4 Not yet recruiting Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Condition: Newly Diagnosed Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Lenalidomide;   Drug: Dexamethasone
5 Recruiting Preservation of Ovarian Function After Hematopoietic Cell Transplant
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease;   Acute Myeloid Leukemia;   Myeloproliferative Disorders
Interventions: Drug: Leuprolide;   Biological: hematopoietic cell transplant;   Biological: reduced intensity allogeneic HCT
6 Terminated Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.
Conditions: Vertebral Fracture;   Multiple Myeloma;   Osteolytic Metastases
Intervention: Device: balloon kyphoplasty
7 Terminated Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
Conditions: Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions: Drug: moxifloxacin hydrochloride;   Drug: Placebo
8 Completed A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Conditions: Lymphoma, Mantle-Cell;   Leukemia, Lymphocytic, Chronic, B-Cell;   Leukemia, Hairy Cell;   Waldenstrom Macroglobulinemia;   Multiple Myeloma
Intervention: Drug: ON01910 Na
9 Completed Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone;   Drug: thalidomide
10 Active, not recruiting Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide and low-dose dexamethasone;   Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles;   Drug: Melphalan, Prednisone and Thalidomide
11 Active, not recruiting S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Conditions: Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma;   Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
12 Unknown  American Ginseng in Treating Patients With Fatigue Caused by Cancer
Conditions: Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: American ginseng;   Other: placebo
13 Completed CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
Conditions: Hematologic Malignancy;   AML;   ALL;   CML;   Multiple Myeloma;   NHL;   Hodgkin's Lymphoma
Intervention: Device: CD+8 T cell depletion
14 Recruiting A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
15 Active, not recruiting Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Bendamustine;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Aspirin;   Drug: Prophylaxis;   Drug: Antibiotic;   Other: Biweekly Follow Up;   Other: Cyclical Follow Up;   Other: Restaging;   Other: Post-Treatment Follow Up
16 Active, not recruiting
Has Results
Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: lenalidomide;   Other: placebo;   Procedure: peripheral blood stem cell transplantation;   Drug: melphalan;   Drug: cyclophosphamide;   Biological: filgrastim
17 Active, not recruiting Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Drug: bortezomib;   Other: laboratory biomarker analysis
18 Active, not recruiting Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone;   Drug: Velcade plus dexamethasone
19 Recruiting ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: ACE-011;   Drug: Lenalidomide;   Drug: Dexamethasone
20 Active, not recruiting Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Conditions: Ovarian Cancer;   Renal Cancer;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Solid Tumors;   Multiple Myeloma;   Lymphoma
Interventions: Drug: Carfilzomib 30 min IV infusion;   Drug: Carfilzomib bolus administration up to 10 min;   Drug: Carfizomib 30 min infusion plus 40 mg/week dexamethasone

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years